IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation
Journal article published in 2024 by
Lih En Hong 
,
Mihir D. Wechalekar ,
Monika Kutyna,
Annabelle Small ,
Kelly Lim ,
Chloe Thompson-Peach ,
Joule J. Li,
Rakchha Chhetri,
Hamish S. Scott ,
Anna Brown ,
Christopher N. Hahn ,
David T. Yeung,
Salvia Sajid ,
Nirmal Robinson ,
Ranjeny Thomas
and other authors.
,
Mihir D. Wechalekar ,
Monika Kutyna,
Annabelle Small ,
Kelly Lim ,
Chloe Thompson-Peach ,
Joule J. Li,
Rakchha Chhetri,
Hamish S. Scott ,
Anna Brown ,
Christopher N. Hahn ,
David T. Yeung,
Salvia Sajid ,
Nirmal Robinson ,
Ranjeny Thomas
and other authors.
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Abstract High prevalence of IDH mutations in seronegative rheumatoid arthritis (RA) with myeloid neoplasm, elevated 2-hydroxyglutarate, dysregulated innate immunity, and proinflammatory microenvironment suggests causative association between IDH mutations and seronegative RA. Our findings merit investigation of IDH inhibitors as therapeutics for seronegative IDH-mutated RA.